Casirivimab

Casirivimab displayed in vitro inhibition of SARS-CoV-2 Spike-pseudotyped virus infection for all tested emergent Spike variants (B.1.1.7, B.1.351, and P.1); however, the efficacy against B.1.351 and P.1 variants was lower.

REGN10987+REGN10933 antibody cocktail

The antibody displayed only a slight reduction in B.1.1.7 variant neutralization. 

The antibody neutralized the Delta variant of SARS-CoV-2 in vitro. 

Although a significant decrease was observed in the antibody’s capacity to neutralize the Iota strain of SARS-CoV-2 compared to the D614G strain, it retained some activity in vitro. The antibody was able to fully neutralize the Iota strain when combined with Imdevimab. 

Predicted to bind SARS-CoV-2 Spike RBD more potently than imdevimab. The combined formulation (REGEN-COV) is predicted to display synergy of its components in RBD-binding capacity. 

Pregnant women with mild to moderate COVID-19 infused with monoclonal antibodies (bamlanivimab and etesevimab – 1 patient or casirivimab and imdevimab – 14 patients) had generally favourable outcomes. Some of the patient experienced adverse reactions, however. Sample size: 15 (pooled with patients treated with other mAbs). 

Solid organ transplant recipients with mild to moderate COVID-19 might benefit from an early monoclonal antibody treatment (casirivimab and imdevimab or bamlanivimab). The difference in 30-day hospitalization rate between the treatment group and the control group was not statistically significant, however. Sample size: 93 + 72 control. Main outcome: Hospitalization within 30 days from COVID-19 diagnosis.

Solid organ transplant recipients with mild to moderate COVID-19 were observed to have generally favourable outcomes after monoclonal antibody treatment (casirivimab and imdevimab or bamlanivimab). Sample size: 73. 

High-risk outpatients treated with monoclonal antibodies were in a lower risk of hospitalization or death due to COVID-19. The treatment safety profile was considered acceptable. Sample size: 200 (pooled with patients treated with other mAbs) + 200 control. Dosage: 2400 mg IV (combined with imdevimab). Main outcome: A composite of COVID-19–related hospitalizations and ED visits within 29 days post-mAb administration (post-initial COVID-19 diagnosis for the control).

The administration of casirivimab/imdevimab in pregnant and postpartum women led to recovery. Sample size: 10. Dosage: A combined dose of 2.4 g (outpatients) or 8 g (inpatients). 

The sera from casirivimab/imdevimab combination-treated individuals displayed in vitro activity against the wild type, Delta, and Omicron BA.2 strains (but not BA.1). 

Significantly lower rates of hospitalization, emergency department visits, and mortality within 28 days of a positive COVID-19 test were observed among the high-risk patients treated with monoclonal antibodies, compared to those who were not. Sample size: 568 (data pooled for patients receiving bamlanivimab or casirivimab/imdevimab) + 1044 control. 

The treatment of high-risk patients using casirivimab/imdevimab combination was associated with lower rates of hospitalization at all selected time points. Sample size: 696 +696 control. Dosage: 1200 mg infusion of each antibody formulation. Main outcome: Hospitalization rates at days 14, 21 and 28 after infusion.

The treatment of a persistent (258 days) COVID-19 patient with follicular lymphoma on an anti-CD20 therapy using casirivimab/imdevimab combination led to negative RT-PCR conversion and clinical improvement. Sample size: 1. 

Clinical benefit was observed in the casirivimab/imdevimab combination-treated high-risk patients. Sample size: 79 +73 control. 

Casirivimab/imdevimab combination treatment was an independent factor for preventing clinical deterioration in mild or moderate COVID-19 patients during the Delta strain surge in Japan. Sample size: 314 + 635 control. Main outcome: Clinical deterioration.

Casirivimab/imdevimab combination treatment was associated with a reduced risk of death or hospitalization in mild or moderate COVID-19 patients during the Delta strain surge. Sample size: 1104 sotrovimab + 2454 casirivimab and imdevimab + 2046 control. Main outcome: Hospitalization or death within 28 days (cohort study part); hospital-free days within 28 days (comparative effectiveness trial part).

Bamlanivimab/etesevimab combination treatment resulted in significantly lower frequency of severe clinical outcomes compared to the casirivimab/imdevimab combination treatment in high-risk mild or moderate COVID-19 patients in the period of the wild-type/Delta strain prevalence. However, casirivimab/imdevimab treatment alone was associated with low rates of severe disease, too. Sample size: 181 + 500 bamlanivimab/etesevimab for comparison. Dosage: 1200 mg IV. Main outcome: Severe outcomes by day 30.

The combined treatment using casirivimab and imdevimab in mild to moderate COVID-19 patients infected with the Delta strain of SARS-CoV-2 generally led to a significant reduction of viral loads in 7 days. Mutational escape was not observed. Sample size: 50. Dosage: 1200 mg IV. 

Monoclonal antibody treatment targeting SARS-CoV-2 Spike (pooled analysis for bamlanivimab and casirivimab/imdevimab) led to improved clinical outcomes in abdominal transplant recipients with COVID-19 (not requiring hospital admission at baseline). Sample size: 34. Dosage: 1200 mg IV. 

The treatment using casirivimab and imdevimab was safe and tolerable and it was associated with reduced risk of clinical progression, compared to bamlanivimab and etesevimab combined treatment. Neither treatment reduced viral loads in 7 days significantly. Sample size: With follow-up data: 111 bamlanivimab and etesevimab + 127 casirivimab and imdevimab. Dosage: 1200 mg IV. 

A patient receiving anti-CD20 monoclonal antibody treatment with refractory COVID-19 was successfully treated using casirivimab and imdevimab. Sample size: 1. 

A single subcutaneous injection of casirivimab/imdevimab provided significant protection against SARS-CoV-2 infection in the community setting. The analysis covers a 8-month pre-Omicron period. Sample size: 841 + 842 placebo. Dosage: 600 mg subcutaneously. 

Early administration of casirivimab and imdevimab in high-risk outpatients infected with SARS-CoV-2 Delta variant resulted in a clinical outcome considered to show the antibodies’ efficacy. Sample size: 217. Dosage: 1200 mg IV. 

The antibody cocktail Casirivimab/Imdevimab administered on day one post Syrian hamster viral challenge significantly decreased the viral titres of SARS-CoV-2 Omicron BA.2 in animals’ lungs. No significant decrease was observed in the case of nasal turbinates, however. 

The Kappa variant of SARS-CoV-2 (E484Q) shows reduced neutralization by casirivimab. However, casirivimab/imdevimab treatment is effective against Kappa and Delta variants B.1.617. 

Administration of monoclonal antibodies significantly prevented progression in asymptomatic patients infected with SARS-CoV-2. Sample size: 43. Dosage: 2 400 mg in 250 mL normal saline and administered as a single intravenous infusion for approximately 1 h. 

The monoclonal antibody displayed efficacy in kidney transplant recipients with a moderate SARS-CoV-2 infection (including the Omicron variant). Casirivimab was combined with imdevimab. Sample size: 47. Dosage: Casirivimab at 1,200u2005mg and imdevimab at 1,200u2005mg administered as an intravenous infusion. 

Monoclonal antibodies (combination of casirivimab and imdevimab) can provide advantages for immunocompromised patient and exhibit consistent positive outcomes. 

Treatment (remdesivir with monoclonal antibodies - casirivimab in combination with imdevimab) was effective in a lung transplant recipient. Sample size: 1. Dosage: 600 mg/600 mg casirivimab/imdevimab on postoperative day 1. 

This is the initial documentation of administering monoclonal antibodies to a patient with cystic fibrosis, which was well-tolerated and resulted in positive clinical outcomes.  Casirivimab was combined with imdevimab. Sample size: 1. Dosage: Casirivimab 1200 mg and imdevimab 1200 mg as a single 1-h intravenous infusion. 

Early initiation of treatment with monoclonal antibodies against the SARS-CoV-2 spike protein is effective and improves prognosis among hematological patients. The mortality of patients with COVID-19 was 3 times lower compared to the control group. Sample size: 88 +  575 control. Dosage: Single dose of 1200 mg of casirivimab/1200 mg of imdevimab. 

Early initiation of treatment with monoclonal antibodies against the SARS-CoV-2 spike protein is effective and improves prognosis among hematological patients. The mortality of patients with COVID-19 was 3 times lower compared to the control group. Sample size: 88 +  575 control. Dosage: Single dose of 1200 mg of casirivimab/1200 mg of imdevimab. 

Treatment (remdesivir with monoclonal antibodies - casirivimab in combination with imdevimab) was effective in a lung transplant recipient. Sample size: 1. Dosage: 600 mg/600 mg casirivimab/imdevimab on postoperative day 1. 

Treatment with casivirimab/imdevimab was effective in patients with the Delta variant. Casirivimab was combined with imdevimab. Sample size: 25. 

In Indian patients, the use of a monoclonal antibody combination for COVID-19 has been found to be both effective and safe. Casirivimab was combined with imdevimab. Sample size: 29. 

Monoclonal antibody treatment efficacious in hospitalized patients with a susceptible SARS-CoV-2 variant in a randomized, open-label, placebo-controlled trial. Casirivimab was administered either by itself or together with imdevimab. Sample size: 804 + 393 placebo. Dosage: Single intravenous dose of 2.4 g casirivimab + imdevimab (1.2 g of each component) or 8.0 g casirivimab + imdevimab (4.0 g of each component). 

Administering monoclonal antibodies as a treatment to pregnant patients suffering from COVID-19 has had positive effects. Casirivimab was combined with imdevimab. Sample size: 7. Dosage: Infusion of either 600 mg or 1200 mg of casirivimab–imdevimab. Main outcome: A time-dependent viral load statistics (virological) and mortality (dependent on defined parameters) (clinical).

Monoclonal antibodies approved under an emergency use authorization, should be considered in unvaccinated pregnant individuals with mild-to-moderate COVID-19 to decrease the risk of severe disease. Casirivimab was combined with imdevimab. Sample size: 2. Dosage:  600 mg (casirivimab + imdevimab) IV. 

After receiving casirivimab/imdevimab treatment for COVID-19, individuals who have been vaccinated have lower rates of hospitalization compared to those who have not received the vaccine.  Sample size: 198 (fully vaccinated)+ 55(partially vaccinated)+ 969 (unvaccinated). 

Among the individuals who received treatment with casirivimab-imdevimab and had mild to moderate COVID-19, there were no cases of worsening symptoms or hospitalization due to COVID-19. Sample size: 25. 

The combination of casivimab and imdevimab ("Ronapreve" formulation) retained greater neutralizing activity against the Delata variant and lower neutralizing activity against the Omicron variant. Sample size: 29. 

Both the vaccinated and unvaccinated cohorts who received casirivimab-imdevimab treatment had lower rates of hospitalization compared to those who did not receive the treatment. Sample size: 112 + 291 control. Main outcome: The proportion of individuals who require hospitalization within 28 days of being diagnosed with COVID-19.

The combination of casirivimab and imdevimab has been found to significantly decrease the progression of the disease in early-stage COVID-19 patients in Japan who have a fever and are at risk of developing severe symptoms. Sample size: 128. Dosage: 600 mg casirivimab with 600 mg imdevimab 600 mg intravenously. Main outcome: Progression to severe COVID-19.

Patients who were infected with the Gamma variant and treated with bamlanivimab/etesevimab had a greater likelihood of being hospitalized or dying than those who were given casirivimab/imdevimab. Sample size: 165. Dosage: Casirivimab (1200 mg) combined with imdevimab (1200 mg). Main outcome: Need for hospitalization related to COVID-19 or death from any cause by day 30.

Administrated casirivimab/imdevimab via subcutaneous injection was linked to a reduced likelihood of hospitalization or death when compared to not receiving these monoclonal antibody treatments. Furthermore, no significant difference was observed in the risk of death, ICU admission, or need for mechanical ventilation within 28 days between patients who received the antibodies via subcutaneous injection versus those who received them intravenously. Sample size: 969 (subcutaneous) + 1216 (intravenous) + 4353 control. Dosage: Subcutaneous injection or intravenous administration of the combined single dose of 600 mg of casirivimab and 600 mg of imdevimab. Main outcome: Hospitalization or all-cause death through day 28.

The use of mAbs as a treatment appears to be both safe and effective in addressing the clinical symptoms of the Delta variant. Sample size: 5. Dosage: Casirivimab (1200 mg) and imdevimab (1200 mg)  IV. 

Monoclonal antibody treatment for COVID-19 can lower the risk of death in patients who are hospitalized. Sample size: 4 839 + 4 946 control. Dosage: Casirivimab 4 g and imdevimab 4 g in a single intravenous infusion. Main outcome: Assessment of 28-day all-cause mortality using treatment-directed analysis, first in patients without detectable antibodies to SARS-CoV-2 and then in the whole population.

The use of monoclonal antibodies and off-label remdesivir in COVID-19 patients with depleted B cells and prolonged infection proved to be effective and well-tolerated. Sample size: 3. Dosage: A single dose of 1,200 mg casirivimab and imdevimab IV and a 5-day course of remdesivir 200 mg IV, then 100 mg daily. 

Due to its insensitivity to mutations carried by the delta spike, casirivimab is able to neutralize the Delta variant. 

Patients with COVID-19 who received monoclonal antibody treatment while being treated as outpatients were considerably less prone to being admitted to the hospital or visiting the emergency department than those who did not receive mAbs. Casirivimab was combined with imdevimab. Sample size: 1344 + 9009 control.